Nanjing Pharmaceutical Group Company LimitedSSE: 600713

(600713)"NANJING PHARMACEUTICAL GROUP COMPANY LIMITED"Announcement on Redemption upon Maturity of Cash Management Products Purchased with Certain Temporarily Idle Raised Funds and Continued Cash Management by Subsidiary

· Issued by Nanjing Pharmaceutical Group Company Limited via Shanghai Stock Exchange

Filed with SSE · Stock code 600713 · · 5 pages · Chinese

Summary by 6ix AI

Nanjing Pharmaceutical Group Company Limited announced the redemption upon maturity of cash management products purchased with temporarily idle raised funds and the continuation of cash management by its subsidiary. The filing outlines the purpose of cash management, the amount involved, and the sources of funds used for these investments. It also discusses the investment risks and control measures in place to mitigate potential financial risks. The company emphasizes that this strategy aims to enhance the efficiency of idle funds while ensuring the safety of the raised funds and supporting ongoing projects.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600713nanjing-pharmaceutical-group-company-limitedannouncement-on-redemption-upon-maturity-of-cash-management-products-purchased-with-certain-temporarily-idle-raised-funds-and-continued-cash-management-by-subsidiary

Release

Announcement on Redemption upon Maturity of Cash Management Products Purchased with Certain Temporarily Idle Raised Funds and Continued Cash Management by Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Nanjing Pharmaceutical Group Company Limited on 6ix

Story so far

Earlier from Nanjing Pharmaceutical

All Nanjing Pharmaceutical news releases